S. Kirby et al., Hematopoietic stem cells with controllable tEpoR transgenes have a competitive advantage in bone marrow transplantation, BLOOD, 95(12), 2000, pp. 3710-3715
In a previous study, it was found that a truncated erythropoietin receptor
transgene (tEpoR tg) enables multilineage hematopoietic progenitor amplific
ation after treatment with erythropoietin (epo) in vitro and in vivo, This
study used competitive bone marrow (BM) repopulation to show that tEpoR tg
facilitates transplantation by hematopoietic stem cells (HSC), individual m
ultilineage colonies, committed myeloid progenitor colonies, and lymphoid c
olonies (pre-B colony-forming units) were grown from the marrow of animals
6 months after they received a 50/50 mixture of transgene and wild-type BM
cells. In epo-treated recipients, the transgene-bearing cells significantly
outcompeted the wildtype cells (84%-100% versus 16%-0%, respectively). In
recipients treated with phosphate-buffered saline, the repopulation was min
imally different from the donor mixture (49%-64% transgene versus 51%-36% w
ild-type). The epo-induced repopulation advantage is maintained in secondar
y transplants. In addition, neither accelerated HSC depletion nor uncontrol
lable proliferation occurred during epo-stimulated serial transplants of tr
ansgene-containing BM, Thus, the tEpoR tg functions in a benign fashion in
HSC and allows for a significant and controllable repopulation advantage in
vivo without excessive HSC depletion relative to wild-type BM. (C) 2000 by
The American Society of Hematology.